The estimated Net Worth of Kenneth H Wilson is at least $996 Thousand dollars as of 3 June 2015. Kenneth Wilson owns over 5,388 units of AMAG Pharmaceuticals stock worth over $625,000 and over the last 10 years Kenneth sold AMAG stock worth over $370,533.
Kenneth has made over 1 trades of the AMAG Pharmaceuticals stock since 2015, according to the Form 4 filled with the SEC. Most recently Kenneth sold 5,388 units of AMAG stock worth $370,533 on 3 June 2015.
The largest trade Kenneth's ever made was selling 5,388 units of AMAG Pharmaceuticals stock on 3 June 2015 worth over $370,533. On average, Kenneth trades about 1,347 units every 0 days since 2014. As of 3 June 2015 Kenneth still owns at least 25,000 units of AMAG Pharmaceuticals stock.
You can see the complete history of Kenneth Wilson stock trades at the bottom of the page.
Kenneth's mailing address filed with the SEC is C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM, MA, 02451.
Over the last 18 years, insiders at AMAG Pharmaceuticals have traded over $162,079,471 worth of AMAG Pharmaceuticals stock and bought 3,622,220 units worth $65,172,892 . The most active insiders traders include Capital, Llc Armistice Capi..., Capital Partners Gp, L.L.C...., and Capital Management Lp Camber. On average, AMAG Pharmaceuticals executives and independent directors trade stock every 42 days with the average trade being worth of $2,148,850. The most recent stock trade was executed by Capital Management Lp Camber on 1 October 2020, trading 4,390,000 units of AMAG stock currently worth $59,572,300.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the manufacture, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia. It manufactures, develops, and commercializes products derived from its proprietary technology for use in treating human diseases. Its products include Intrarosa, Vyleesi, Makena, CBR, Feraheme, and MuGard. The company was founded on November 9, 1981 and is headquartered in Waltham, MA.
AMAG Pharmaceuticals executives and other stock owners filed with the SEC include: